Clinical effectiveness of pharmacist administration of long‐acting injectable buprenorphine: Findings from the EPIC‐MATOD study

Documenti analoghi

• What influences Australian pharmacists' decisions to supply opioids? Results from a survey and randomised controlled factorial experiment
  di: Louisa Picco, et al.
  Pubblicazione: (2025)
• Making long‐acting treatment work: Tracing connections with extended‐release buprenorphine depot through time
  di: Sandra Gendera, et al.
  Pubblicazione: (2025)
• Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open‐label, non‐randomised trial of long‐acting injectable buprenorphine treatment in Australian custodial settings
  di: Bethany White, et al.
  Pubblicazione: (2025)
• Provider costs of treating opioid dependence with extended‐release buprenorphine in Australia
  di: Stella Settumba, et al.
  Pubblicazione: (2024)
• Stocking and supplying naloxone: Findings from a representative sample of community pharmacies in Victoria, Australia
  di: Nandini Karthikeyan, et al.
  Pubblicazione: (2024)